

NZX/ASX Announcement

2 October 2026

Resignation of CEO, Martin Dillon

TruScreen Group Limited (NZX/ASX: TRU), (“TruScreen” or “the Company”), a global leader in AI-enabled cervical cancer screening, advises that for personal reasons, Martin Dillon, Chief Executive Officer (CEO), has resigned from the Company with effect from 31 October 2026.

Tony Ho, Non-Executive Independent Chairman, will assume the responsibilities of Executive chairman and Interim CEO while the Company undertakes a recruitment process for a new Chief Executive Officer.

The Board is confident that TruScreen’s executive team will continue to manage the Company’s operations and strategic priorities during the transition period. Mr Dillon will remain a consultant to the Company to provide support following his departure, if required.

Commenting on the announcement, Mr Ho said:

“On behalf of the Board, I thank Martin for his significant contribution to TruScreen over many years, particularly in the past year, the opening of new markets in Central Asia, Indonesia, India, Malaysia, Thailand and greater Africa.

We respect his decision and recognise that his personal wellbeing is important. Stakeholders would be aware that Martin lost his spouse in June 2026. We wish him every success for the future.”

The Board will provide further updates to the market as appropriate.

Approved for release by the Board.

Tony Ho
Executive Chairman

For more information, visit www.truscreen.com or contact:

Tony Ho
Executive Chairman
tonyho@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

For personal use only

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen's cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra®, is registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen technology has been recognised in CSCCP's (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guideline.

TruScreen has been recognised in a China Blue Paper "Cervical Cancer Three Stage Standardized Prevent and Treatment" published on 28 April 2023.

In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National Technical List, for use in Vietnam's public and private healthcare sectors and in 2024 was added to the Russian guidelines for the screening of cervical cancer.

In financial year 2024 alone, over 200,000* examinations were performed with the TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen's vision is "A world without the cervical cancer".

To learn more, please visit: www.truscreen.com/.

**Based on Single Use Sensor sales.*